{"schema_version":"secwatch.filing_event.v1","accession":"0001420800-24-000019","form_type":"8-K","ticker":"ENOV","cik":"0001420800","company_name":"Enovis CORP","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.002166+00:00","generated_at":"2026-05-31T11:41:17.016651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77","bullets":["Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.","Reported net loss from cont ops $0.34/sh; adjusted EPS $0.62; adj EBITDA $90M (17.2% of sales, +190bps).","Raised FY2024 adj EPS guidance to $2.62-$2.77 (from $2.52-$2.67); revenue narrowed to $2.08-$2.13B.","Received FDA 510k clearance for Arvis 2.0 Shoulder and Altivate Reverse Glenoid; launches expected Q3 2024.","Opened new manufacturing facility in San Daniele and Business Technology Center in Lisbon."],"urls":{"canonical":"https://secwatch.observer/filing/0001420800-24-000019","json":"https://secwatch.observer/filing/0001420800-24-000019.json","markdown":"https://secwatch.observer/filing/0001420800-24-000019.md","text":"https://secwatch.observer/filing/0001420800-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420800/000142080024000019/0001420800-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420800/000142080024000019/cfx-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:41:17.016651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}